Table 3.

Overall antidrug antibody results

Variable	ABP 798	Rituximab RP
Patients with a binding antibody negative or no result at baseline and a post-baseline result	126	123
Developing antibody incidence, n (%)
Binding antibody positive post-baseline	3 (2.4)	1 (0.8)
Transienta	2 (1.6)	0 (0.0)
Neutralizing antibody positive anytime	1 (0.8)	1 (0.8)
Transienta	1 (0.8)	0 (0.0)

Baseline was defined as the last non-missing assessment taken prior to the first dose of investigational product. Percentages were calculated using the corresponding category count as the denominator

RP reference product

^aNegative result at the subject’s last time point tested within the study period